I have invested some time in trying to decipher the UNS Commercial Pipeline ,as presented at the 2012 AGM , and re-issued in Jan ’13 .
As at Jan’13 our Commercial Pipeline anticipated the following Programs with 2013 revenues targeted :
Prefills :5 actually delivered ... 2
: 10/9/13 .........SANOFI ( Customer I ).......Peak sales pa ........$50mm
: 21/11/13 ........HIKMA ( Customer A )......Peak sales pa ........$70mm
Bolus : 4 actually delivered.....1 : 12/11/13 ........Medimmune ( Customer C ) Peak sales pa......$75mm
Auto Injectors : 1 actually delivered.....0
Drug Reconstitution : 1 actually delivered..1
: 09/4/13........Unamed ........(Customer ?) Peak Sales pa........$20mm
Targeted Delivery....: 2 actually delivered..2
: 03/12/13.......Novartis.........( Customer T) Peak sales pa........$75mm
:17/12/13........Regeneron (imo) (Customer D) Peak sales p.....$20mm
SUMMARY 2013 : Expected 13 : Actual 6 : Peak sales total pa $ 310mm
: Outstanding : 7 :Peak sales total pa
$ 265mm
SUMMARY 2014 : Expected : 16 : Peak sales total pa $ 370 mm
2014 = very busy year : Expected 23 new contracts worth a total of $ 635mm to be announced .
GLTA
Q
- Forums
- ASX - By Stock
- UNS
- 2014 contract outlook
2014 contract outlook
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)